Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.17 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $34.36 million versus the consensus estimate of $8.01 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.